A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

NCT01777243 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis

Interventions

DRUG: GSK2398852
DRUG: GSK2315698

Sponsor

GlaxoSmithKline

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]